EXERT-BC Protein: Protein Supplementation to Improve Body Composition After Treatment for Breast Cancer
EXERT-BC Protein: Randomized Study of Protein Supplementation to Improve Body Composition Improvement During Hypertrophy Exercise After Treatment for Breast Cancer
In this study, the investigators hypothesize that a high dose of post-workout protein after each exercise session will have greater improvements in changes in body composition, including muscle mass and percent body fat versus a workout alone.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Clinical Trials Contact
- 전화번호: 412-330-6151
- 이메일: ctgov@ahn.org
연구 장소
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15212
- 모병
- AHN Allegheny General Hospital
-
연락하다:
- Clinical Trials Contact
- 전화번호: 4123306151
- 이메일: ctgov@ahn.org
-
Pittsburgh, Pennsylvania, 미국, 15212
- 아직 모집하지 않음
- AHN Allegheny General Hospital
-
연락하다:
- Clinical Trials Contact
- 전화번호: 412-330-6151
- 이메일: ctgov@ahn.org
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age 20-89 years
- Women prescribed exercise as a SOC
- Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast
- Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.
- Women with > 3 months of resistance training experience under expert guidance by a CSCS
- Must be able to read and understand English and consent for themselves.
Exclusion Criteria:
- Any current treatment with cytotoxic chemotherapy for breast cancer
- Inability to safely engage in group sessions of resistance training as deemed by study PI
- Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training
- Beta blocker or GLP-1 inhibitor medications
- Pregnant women
- Males
- Lactose intolerance
- Cow's milk or whey protein allergy
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 다른
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: 60 grams of protein
Participants will be randomized to a post-workout protein consisting of either no protein or 60 g of whey protein. The protein is 100% cold processed and micro-filtered, non-GMO grass-fed whey protein isolate, soy and gluten free, unflavored, and unsweetened. This will include Irish Dairy (AGN Roots, Ireland), which is whey protein isolate and soy lecithin, and Raw GrassFed Whey, which is whey protein concentrate. Utilizing both will allow individuals with any sensitivity to have increased options. The powder will be weighed by EOC staff in a private room prior to mixing with 12 oz of filtered water to ensure adequate dosage. The protein will be mixed via a protein shaker bottle made of stainless steel (Bolde Bottle). |
60 grams of whey protein |
|
실험적: 0 grams of protein
Participants will be randomized to a post-workout protein consisting of either no protein or 60 g of whey protein. The protein is 100% cold processed and micro-filtered, non-GMO grass-fed whey protein isolate, soy and gluten free, unflavored, and unsweetened. This will include Irish Dairy (AGN Roots, Ireland), which is whey protein isolate and soy lecithin, and Raw GrassFed Whey, which is whey protein concentrate. Utilizing both will allow individuals with any sensitivity to have increased options. The powder will be weighed by EOC staff in a private room prior to mixing with 12 oz of filtered water to ensure adequate dosage. The protein will be mixed via a protein shaker bottle made of stainless steel (Bolde Bottle). |
0 grams of whey protein |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Determine changes in pounds of muscle and fat mass after each exercise regimen
기간: Baseline and at program completion (within 4 weeks of exercise completion)
|
Baseline and at program completion (within 4 weeks of exercise completion)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Determine changes in resting metabolic rate in calories per day at the completion of the exercise regimen
기간: Baseline and at program completion (within 4 weeks of exercise completion)
|
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
|
Determine changes in body composition at the completion of the exercise regimen, including body mass in pounds, fat mass in pounds, fat-free mass in pounds, % fat, and % fat-free mass
기간: Baseline and at program completion (within 4 weeks of exercise completion)
|
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
|
Determine changes in Y-balance score at the completion of the exercise regimen
기간: Baseline and at program completion (within 4 weeks of exercise completion)
|
Y-Balance score measures the length an individual can extend their foot. The larger the score the better the balance. |
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
Functional Movement Screen (FMS) scores at the completion of the exercise regimen
기간: Baseline and at program completion (within 4 weeks of exercise completion)
|
FMS measures movement patterns with scoring from 0 to 21. The large the score the better the mobility. |
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
Determine changes in phase angle at the completion of the exercise regimen
기간: At program completion (at 8 weeks)
|
Phase angle measures the fluidity of cells and the larger the value the better. |
At program completion (at 8 weeks)
|
공동 작업자 및 조사자
스폰서
스폰서
수사관
수사관
- 수석 연구원: Colin Champ, MD, CSCS, AHN Radiation Oncology
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 2026-159-SG
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .